Flexible Ti3C2Tx-Polyurethane Electrodes for Versatile Wearable Applications.

With the development of science and technology, wearable electronics are increasingly widely used in medical, environmental monitoring, and other fields. Thus, the demand for flexible electrodes is increasing. The two-dimensional material Ti3C2Tx has attracted much attention in the manufacture of flexible electrodes due to its excellent mechanical and electrical properties. However, the brittleness of pure Ti3C2Tx films has become a major obstacle for their use as flexible electrodes in wearable devices. Therefore, solving the brittleness problem of flexible electrodes based on Ti3C2Tx while maintaining the excellent performance of Ti3C2Tx has become an urgent problem. To solve this problem, Ti3C2Tx was compounded with waterborne polyurethane (WPU), and a Ti3C2Tx-WPU composite film with a hierarchical structure was constructed by evaporation-assisted self-assembly. The Ti3C2Tx-WPU composite film not only retains the excellent electrical conductivity of Ti3C2Tx (100 S m-1) but also has flexibility (20 MJ m-3). Furthermore, the Ti3C2Tx-WPU composite film is applied to functional devices such as contact pressure sensors and non-contact proximity sensors. Finally, the Ti3C2Tx-WPU composite film wearable device demonstrates its practical application potential in the field of wearable devices.

Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy.

The adeno-associated virus (AAV) is a defective single-stranded DNA virus with the simplest structure reported to date. It constitutes a capsid protein and single-stranded DNA. With its high transduction efficiency, low immunogenicity, and tissue specificity, it is the most widely used and promising gene therapy vector. The clustered regularly interspaced short palindromic sequence (CRISPR)/CRISPR-associated protein 9 (Cas9) gene editing system is an emerging technology that utilizes cas9 nuclease to specifically recognize and cleave target genes under the guidance of small guide RNA and realizes gene editing through homologous directional repair and non-homologous recombination repair. In recent years, an increasing number of animal experiments and clinical studies have revealed the great potential of AAV as a vector to deliver the CRISPR/cas9 system for treating genetic diseases and viral infections. However, the immunogenicity, toxicity, low transmission efficiency in brain and ear tissues, packaging size limitations of AAV, and immunogenicity and off-target effects of Cas9 protein pose several clinical challenges. This research reviews the role, challenges, and countermeasures of the AAV-CRISPR/cas9 system in gene therapy.